Industry news that matters to you.  Learn more

Archives for May 2011

Protein Biomarker Producer Revolutionizes Early Detection of Gastric and Stomach Cancer

Lee BioSolutions, an international producer and supplier of high purity proteins, biological, biochemicals, antibodies and coenzymes, today announced a major scientific breakthrough. The St. Louis-based biotechnology firm recently developed a proprietary process to effectively and efficiently purify and stabilize two important gastric cancer protein biomarkers. As a result, Lee is mass producing Pepsinogen I and Pepsinogen II, critical components in serum pepsinogen tests that will revolutionize early detection of stomach and gastric cancer.

NextGen Sciences Launches Multiple Protein Plasma Biomarker Assay for Multiple Sclerosis

NextGen Group plc is pleased to announce that its subsidiary NextGen Sciences Inc, a leader in biomarker discovery, measurement and qualification, has launched the first phase of its multiple protein (multiplex) assays in plasma, for CNS diseases. The plasmamultiplesclerosis15 assay simultaneously measures 15 human plasma proteins that are thought to have potential as biomarkers in multiple sclerosis disease. The launch of plasmamultiplesclerosis15 is part of NextGen Sciences strategy of becoming a leading player in the growing central nervous system (CNS) and oncology biomarker markets.

Fujirebio Diagnostics, Inc. Receives FDA 510(k) Clearance for First Biomarker to Monitor Lung Cancer

Fujirebio Diagnostics, Inc., today announced that the U.S. Food and Drug Administration (FDA) has granted 510 (k) clearance to the CYFRA 21-1™ EIA assay to monitor disease progression during the course of disease and treatment of lung cancer patients. This is the first biomarker assay kit to be cleared by FDA for use in the management of patients with lung cancer.

Amarantus BioSciences Announces Partnership Agreement with Generex Biotechnology

Amarantus BioSciences, Inc. (“Amarantus”), a biotechnology company developing first-in-class, disease-modifying treatments that address an underlying cause of cell death known as apoptosis, today announced a licensing agreement under which Amarantus will in-license Generex Biotechnology, Inc.’s (“Generex”) drug delivery technologies in all therapeutic areas, excluding diabetes mellitus, where Generex and Amarantus will pursue a joint research collaboration.

Quintiles and Population Genetics Technologies Enter into Partnership

Quintiles, a biopharmaceutical services company, and Population Genetics Technologies Ltd.(PGT), creator of innovative solutions to reduce the costs and complexity of large-scale genomic testing and enable correlations with clinical outcomes, recently announced a commercial collaboration to bring genomic testing into mainstream drug development in order to produce safer, more effective medicines.